Skip to contentC
CytomX Therapeutics, Inc.
C
CTMXCytomX Therapeutics, Inc. Q2 2024 · 10-Q
Revenue$25.12M$25.12M+1.6% vs Q2 2023 Net Income-$6.53M-$6.53MN/M vs Q2 2023 EPS Diluted-$0.08-$0.08N/M vs Q2 2023 Operating Income-$8,452,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CytomX Therapeutics, Inc. · CIK 1501989 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$19,645,000N/M Margins · derivedOperating margin-33.7%−20.1 pt vs Q2 2023
Net margin-26.0%−21.6 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 8, 2024 · 39 d after period end